Clinical trial · Observational
11C-Acetate PET/CT Non-FDG-Avid Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
F18-FDG is the widely used PET tracer in the routine practice of oncologic disease imaging using the technology of PET-CT. However, FDG-avidity is a characteristic of the individual tumor. There are various types of human malignancies, which are not taking FDG in access. In these cases FDG is not a sensitive tracer of imaging. In search for other tumor PET tracers, C11-Acetate has been shown recently in a few early studies to have a potential value in imaging of non-FDG-avid tumors. The purpose of the current study is to assess the role of 11C-acetate PET in various tumors, which often are not detected by 18F-FDG and were not widely assessed until now.
Conditions
Conditions (10)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Hepatocellular | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Carcinoma, Lobular | Breast Lobular Carcinoma | ALIAS | 0.90 |
| GIST | Gastrointestinal Stromal Tumor | ALIAS | 0.90 |
| Indolent Lymphoma | Indolent Non-Hodgkin Lymphoma | ALIAS | 0.90 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Neuroendocrine Tumors | Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.90 |
| Soft Tissue Sarcomas | Soft Tissue Sarcoma | ONTOLOGY_EXACT | 0.90 |
| Teratoma | Teratoma | ONTOLOGY_EXACT | 0.90 |
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- 1
- description
- 100 patients with newly diagnosed tumors, which are often non-FDG avid or show only low intensity uptake: Soft tissue sarcomas, well-differentiated thyroid cancer, well-differentiated and bronchoalveolar lung cancer, indolent lymphomas, neuroendocrine tumors, GIST, uterine malignancies, mucin-producing cancer, teratoma, hepatoma, HCC and lobular breast carcinoma.
Primary outcomes (1)
- measure
- Uptake of C11-Acetate and F18-FDG in tumor will be measured in SUV PET units
- timeFrame
- At completion of acuisition
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * patients with newly diagnosed tumors, which are often non-FDG avid or show only low intensity uptake: * Soft tissue sarcomas * well-differentiated thyroid cancer * well-differentiated and bronchoalveolar lung cancer * indolent lymphomas * neuroendocrine tumors * GIST * uterine malignancies * mucin-producing cancer * teratoma * hepatoma * HCC * lobular breast carcinoma * Patients over the age of 18 Exclusion Criteria: * patients under the age of 18 years * pregnant and lactating women * claustrophobic patients
References
Publications (0)
Data not yet available